3′,4′-Methylenedioxy-α-pyrrolidinopropiophenone (MDPPP) is a stimulant designer drug. During the late 1990s and early 2000s, it was available in Germany and often used as an ingredient in counterfeit ecstasy (MDMA) tablets. MDP resembles the chemical structure of α-PPP and MDPV and has demonstrated reinforcing effects in rat studies.
|Chemical and physical data|
|Molar mass||247.294 g·mol−1|
MDPPP seems to undergo a metabolic pathway akin to that of MDPV.
By October 2015, MDPPP had been classified as a controlled substance in China.
1. What is MDPPP?
MDPPP, short for 3′,4′-Methylenedioxy-α-pyrrolidinopropiophenone, is a synthetic stimulant designer drug.
2. How does MDPPP compare to other designer drugs?
MDPPP is part of the designer drug category, and it shares certain structural similarities with other compounds like MDPV and α-PPP.
3. What are the effects of MDPPP use?
MDPPP is known for its stimulant effects, which may include increased energy, alertness, and sometimes a sense of euphoria. However, it can also have adverse effects and pose health risks.
4. What is the legal status of MDPPP?
The legal status of MDPPP varies by country and jurisdiction. For example, as of October 2015, it was classified as a controlled substance in China. Always consult local and national drug laws to determine its current legality.
5. Are there any known health risks associated with MDPPP use?
Using MDPPP can carry potential health risks, including an increased heart rate, elevated blood pressure, anxiety, and a risk of addiction or dependence with prolonged or heavy use.
6. Is MDPPP addictive?
Like many other stimulant drugs, MDPPP has the potential for addiction and dependence, especially with frequent or heavy use. Users should be cautious and informed about this risk.
7. How can the risks associated with MDPPP use be minimized?
The best approach to minimize risks is to avoid using MDPPP altogether. If someone chooses to use it, they should be well-informed about potential dangers, use it in moderation, and avoid combining it with other substances. Harm reduction strategies and a support system can be beneficial.
8. Where can I find more information about MDPPP?
For more information about MDPPP, consider consulting medical professionals, addiction support organizations, or drug education resources. Always prioritize your health and safety when considering substance use and seek assistance.
- In August 2003, a study by Springer, Fritschi, and Maurer explored the metabolism and toxicological detection of the novel designer drug 3′,4′-methylenedioxy-alpha-pyrrolidinopropiophenone. The research focused on urine analysis employing gas chromatography-mass spectrometry. This study was published in the “Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences,” Volume 793, Issue 2, spanning pages 377–88. The DOI is 10.1016/S1570-0232(03)00350-7, and the PMID is 12906913.
- In April 2004, Maurer, Kraemer, Springer, and Staack provided a comprehensive synopsis covering the chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs falling into the amphetamine (ecstasy), piperazine, and pyrrolidinophenone categories. This review was featured in “Therapeutic Drug Monitoring,” Volume 26, Issue 2, on pages 127–31. The DOI is 10.1097/00007691-200404000-00007, and the PMID is 15228152. Additionally, it’s accessible via S2CID 9255084.
- In June 2005, Staack and Maurer delved into the metabolism of designer drugs of abuse. Their insights can be found in “Current Drug Metabolism,” Volume 6, Issue 3, across pages 259–74. The DOI is 10.2174/1389200054021825, and the PMID is 15975043.
- A study conducted in March 2005 by Springer, Staack, Paul, Kraemer, and Maurer identified cytochrome P450 enzymes involved in the metabolism of 3′,4′-methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP), a designer drug. Human liver microsomes were used in this research, and the findings were published in “Xenobiotica; the Fate of Foreign Compounds in Biological Systems,” Volume 35, Issue 3, on pages 227–37. The DOI is 10.1080/00498250400028239, and the PMID is 16019948. The study can also be accessed via S2CID 28207896.
- In May 2018, Gannon, Galindo, Mesmin, Sulima, Rice, and Collins conducted research on the relative reinforcing effects of second-generation synthetic cathinones. Their study examined the acquisition of self-administration and fixed ratio dose-response curves in rats. The findings were documented in “Neuropharmacology,” Volume 134 (Pt A), with relevant content spanning pages 28–35. The DOI is 10.1016/j.neuropharm.2017.08.018, and the study is available through PMC with PMID 28811192.
- On September 27, 2015, the China Food and Drug Administration released a notification titled “关于印发《非药用类麻醉药品和精神药品列管办法》的通知” (in Chinese). This notification outlines regulations concerning non-medicinal narcotic drugs and psychotropic drugs, including substances like MDPPP. The information is based on the original document, which was archived on October 1, 2015.